Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/07/055661
CTRI/2023/07/055661
Not Yet Recruiting
Phase 2

Improving health outcomes among older adults inIndia: effectiveness and implementability of a novel Comprehensive GeriatricAssessment based intervention - EHSAS pilot trial

Dr Jaya Singh Kshatri0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Jaya Singh Kshatri
Status
Not Yet Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Jaya Singh Kshatri

Eligibility Criteria

Inclusion Criteria

  • •We will include all permanent residents of the selected cluster who are 60 years or above of age as participants for the trial.
  • •The participants should be able to provide written informed consent and agree to follow up for 24 months

Exclusion Criteria

  • •We will exclude those with severe cognitive impairment (as assessed by the Dementia assessment rapid test\- DART), those unable to comprehend/communicate, seriously ill/bed ridden patients and those who plan to move out of the study site during the trial period.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Improving health and well-being of elderly patients through nurse-led discharge plan and follow-up care: a Randomised Controlled TrialWell-being in the elderly
SLCTR/2017/011niversity of Sri Jayewardenepura
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-BESaarland University388
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-002272-27-ATSaarland University388
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-PTSaarland University388
Active, Not Recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible forhigh-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma infirst Relapse or Progression by adding Nivolumab to Gemcitabine,Oxaliplatin plus Rituximab in case of B-cell lymphoma.
EUCTR2016-002272-27-PLSaarland University388